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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S2848 weeks post treatment. Blood samples were screened to detect the
replication competent retrovirus (RCR), retrovirally transduced cells
and TGF-b1 protein starting from 2 weeks up to 6 months post
treatment. Safety measures including physical exams, complete blood
count, and serum chemistry were included up to 6 months post
treatment.
Results: TG-C signiﬁcantly improved IKDC, WOMAC, and 100 mm VAS
scores. Low and high doses of TG-C treatment showed signiﬁcant
improvement in total IKDC score by 33% (from 44.9  7.8 to 59.93 
10.5, p<0.001) and by 25% (from 49.9 2  9.5 to 62.48  9.7, p<0.001),
respectively, at 6 month post treatment. Low and high doses of TG-C
treatment showed signiﬁcant improvement in WOMAC scores by 45%
(from 31.92  8.4 to 17.43  8.2, p<0.001) and by 41% (from 30.00  9.5
to 17.79  9.7), respectively, at 6 month post treatment. Low and high
doses of TG-C treatment also improved 100mmVAS scores from by 47%
(51.07  13.4 to 26.50  14) and by 45% (from 50.77  13.3 to 28.14
11.2), respectively, at 6 month post treatment. No SAEs were shown in
the treatment groups.
Conclusions: The current phase IIa study indicated that TG-C improved
three evaluation criteria for pain, sports activities, and quality of daily
life in patients with osteoarthritis without showing SAEs.
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THE INTENSIVE DIET AND EXERCISE FOR ARTHRITIS TRIAL (IDEA):
EFFECTS ON KNEE JOINT LOADING AND INFLAMMATION
S.P. Messier 1, P. DeVita 2, B.J. Nicklas 3, D. Beavers 3, S. Mihalko 1,
G.D. Miller 1, M. Lyles 3, D.J. Hunter 4, F. Eckstein 5, C. Legault 3,
J.D. Williamson 3, J.J. Carr 3, R.F. Loeser 3. 1Wake Forest Univ., Winston-
Salem, NC, USA; 2 East Carolina Univ., Greenville, NC, USA; 3Wake Forest
Univ. Sch. of Med., Winston-Salem, NC, USA; 4Univ. of Sydney, Sydney,
Australia; 5 Paracelsus Med. Univ., Salzburg, Austria
Purpose: Overweight and obesity is the most modiﬁable risk factor for
symptomatic knee osteoarthritis (OA), and dietary induced weight loss
combined with exercise is potentially the best non-pharmacologic
treatment. We report the mechanistic primary outcomes of a long-term
(18 month) study designed to test the hypothesis that intensive weight
loss, either with or without exercise, will reduce knee joint loads and
serum levels of inﬂammatory biomarkers compared to an exercise only
control group in older, overweight and obese adults with symptomatic
knee OA.
Methods: The Intensive Diet and Exercise for Arthritis trial (IDEA) was
a prospective, single-blind, randomized controlled trial that enrolled
454 overweight and obese (BMI ¼ 27-40.5 kg/m2) older (age  55 yrs)
adults with pain and radiographic evidence of tibiofemoral OA (KL ¼
2-3). Participants were randomized to one of three 18-month inter-
ventions: intensive dietary restriction-only (D); intensive dietary
restriction-plus-exercise (D+E); or exercise-only control (E). The
weight loss goal for the two diet groups was  10% of baseline body
weight. The exercise intervention consisted of low to moderate
intensity walking and resistance training 3 d/wk for 1 hr/d. High
speed motion analysis and musculoskeletal modeling were used to
calculate knee joint loads, and fasting serum concentrations of
inﬂammatory biomarkers were measured by enzyme-linked immu-
nosorbent assays. We used an intention-to-treat analysis to compare
differences between groups in changes from baseline (at 6 and 18
month follow-up combined) after adjusting for gender, baseline BMI,
visit (6 and 18 months), and baseline values of the dependent variable
using repeated measures ANCOVA.
Results: Mean baseline descriptive characterisitics of the cohort
included: age, 65.6 yrs.; BMI, 33.6 kg/m2; 72%female; 81%white. A
total of 399 (88%) participants completed the study and returned for
FU18 testing. Mean weight loss was: D, 9.5%; D+E, 11.4%; E, 2.2%.
Mean (SE) IL-6 (pg/mL), the primary inﬂammatory outcome, was
signiﬁcantly changed in the D, -0.43 (0.11) and D+E, -0.36 (0.11)
groups compared to the E, 0.04 (0.11) group (p ¼ 0.005). Similarly,
Leptin (ng/mL) also signiﬁcantly changed in the D, -13 (2) and D+E,
-14 (1) groups relative to the E, -3 (1) group (p < 0.0001). Knee
compressive force (N/step), the primary mechanical outcome, was
signiﬁcantly reduced in the D, -174 (42) and D+E, -51 (40) groups
compared to the E, 154 (41) group (p < 0.0001). Results from the
musculoskeletal model revealed that the differences in knee
compressive forces were associated to signiﬁcant changes (N/step)
in hamstring muscle force (D, -56 (18); D+E, 3 (17); E, 71 (17):
p < 0.0001), gastrocnemius force (D, -43 (6); D+E, -39 (5); E, 12 (5):p < 0.0001), and quadriceps forces (D, -46 (28); D+E, 27 (26); E, 121
(27): p < 0.0001). Changes in the peak internal abductor moment
(Nm), a commonly used surrogate of medial compartment joint
loading, were not different between the groups (D, 0.33 (0.72); D+E,
1.51 (0.69); E, 0.49 (0.70): p ¼0.4), primarily due to heterogeneity in
frontal plane knee alignment among the participants.
Conclusions:This trial shows that intensive weight loss, with or
without exercise, signiﬁcantly impacts both the mechanical and
inﬂammatory OA disease pathways by reducing knee joint compressive
loads and IL-6, respectively. While exercise is effective in improving
clinical outcomes in this population, our data indicate that intensive
weight loss, not exercise, is the non-pharmacologic treatment that
signiﬁcantly impacts both OA disease pathways.
Supported by grants from NIH R01 AR052528, P30 AG21332, M01
RR00211
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EFFICACY AND SAFETY OF LONG-TERM REPEATED, INTRA-
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Purpose: A clear picture about the beneﬁts of repeated courses of
Hyaluronic Acid (HA) on osteoarthritis (OA) is pending to be drawn.
AMELIA (Arthrosis Modifying Effects of Long-term Intra-articular
Adant) is a recently completed multicentre, double-blind, placebo-
controlled clinical trial with a 40 months follow-up to assess the efﬁ-
cacy and tolerability of repeated administration of intra-articular
injections of Adant or placebo in knee osteoarthritis.
Methods: Patients with primary knee osteoarthritis (ACR criteria),
radiological grades II-III according to Kellgren scale and joint space
width >¼2 mm were randomised 1:1 to receive 4 cycles of 5 intra-
articular Adant or placebo (saline) injections each one. The follow up
periods were 6 months long after the ﬁrst and second cycles and 1
year long after the third and fourth ones making total study duration
of 40 months (Figure 1). OMERACT-OARSI 2004 responder criteria
were used for efﬁcacy evaluation. Adverse events were recorded for
safety purposes and monitored until resolution.).
Results: From 446 screened, a total of 306 patients were randomized
and allocated to Adant or placebo. Both groups were homogeneous at
baseline for demographics and OA characteristics (see ARD Nov 2011 for
further details) and a total of 203 patients completed the study
procedures.
At the end of follow-up, signiﬁcantly more patients receiving Adant
responded to treatment in comparison to placebo according to OMER-
ACT-OARSI 2004 criteria (p¼0.004), the number of responders being
22% higher in HA group (RR 1.22; CI 95% 1.07 to 1.41). Signiﬁcant
differences were also found in favour of HA for each individual
component of the OMERACT-OARSI 2004: pain, function and patient
global assessment with p values of 0.025, 0.023 and 0.002 respectively.
Responders to HA injections progressively increased after each treat-
ment cycle (from 71.1% to 80.5%) whereas responders to placebo
remained fairly stable (from 67.8% to 65.8%) providing statistically
signiﬁcant differences between both groups through the study period
(Figure 2). Dropouts due to lack of efﬁcacy were statistically signiﬁcant
lower in HA group (p¼0.026). Paracetamol was consumed by 48% of the
patients and the mean daily dose during the study experienced a 27%
reduction in the HA group compared to baseline versus only a 4% in the
placebo group.
Twenty-two patients (11 per group) experienced a total of 29 related
adverse events, the rate of related adverse events/cycle being 0.029 in
both groups. Most of them were related with the study intervention,
such as local bleeding, pain of mild intensity or allergic reaction and
none of them serious.
Conclusions: AMELIA trial evidence the superiority of Adant to
placebo. Repeated cycles of intra-articular injections of this HA not only
improve knee OA symptoms during the in-between cycle period, but
also exert a marked carry over effect lasting for at least one year after
the last cycle. Adverse reactions were scarce and related to the
administration procedure.
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PREVENTION OF KNEE OSTEOARTHRITIS IN OVERWEIGHT FEMALES;
THE FIRST PREVENTIVE RANDOMIZED CONTROLLED TRIAL
J. Runhaar 1, M. van Middelkoop 1, D. Vroegindeweij 2, E.H. Oei 1,
M. Reijman 1, G.J. van Osch 1, B.W. Koes 1, S.M. Bierma-
Zeinstra 1. 1 Erasmus MC, Rotterdam, Netherlands; 2Maasstad Hosp.,
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Purpose: With increasing rates of obesity, continued aging of the
population and a lack of available disease modifying interventions for
osteoarthritis (OA), primary prevention of OA is of great signiﬁcance.
Obesity is known to be one of few modiﬁable risk factors for incident
knee OA. The purpose of the present study was to evaluate the effect of
a pragmatic tailor made weight reduction program and of oral glucos-
amine sulphate (double blind; placebo-controlled), in a factorial design,
on the incidence of knee OA over 2.5 years of follow-up in overweight,
middle-aged females; free of clinical and radiological knee OA at
baseline (ISRCTN 42823086). Worldwide, this is the ﬁrst large RCT on
prevention of knee OA. Here we present the effects of the weight
reduction program.
Methods: 50 general practitioners in the area of Rotterdam, the
Netherlands, contacted all women between 50 and 60 years registered
at their practice (6691 women). All women with a self reported BMI 
27 interested to participate in the study (889 women) were screened on
the inclusion criteria. Subjects had to be free of knee OA according to the
ACR criteria, free of contraindications to MRI, free of rheumatic diseases
and not using oral glucosamine during the past 6 months. In total, 407
women met all inclusion criteria, were invited for baseline measure-
ments and were randomized. Based on baseline standardized semi-
ﬂexed X-rays, all knees with a K&L-grade of  2 were excluded. Half of
all women were randomized into the control group (CG) and received
no intervention onweight reduction. The other half was assigned to the
weight reduction group (WRG) and was referred to a local dietician for
guidance on nutrition and physical activity behaviours based on Moti-
vational Interviewing. In addition, they were invited to join a physical
activity class of 20 weekly group lessons, guided by a physical therapist.
Every 6 months, all 407 subjects received a home visit to measure body
weight, replace study medication and check their well-being. Pre-
speciﬁed primary outcome measure was incidence of knee OA, deﬁned
by incidence of either K&L-grade 2, joint space narrowing of 1.0mm
or clinical knee OA according to the ACR criteria.
Results: At baseline, subjects were 55.7  3.2 years old, had a mean
body weight of 88.7  13.2 kg and a mean BMI of 32.4  4.3 kg/m2;
Ăequally spread over both groups. All 2.5 year follow-up measurements
have been completed (10% lost to follow-up). Almost 75% of WRG
attended the physical activity class at least once (0 to 21 lessons; 7 on
average). Ninety percent visited the dietician at least once (0 to 32
visits; 6 on average). After 2.5 years and on all intermediary measure-
ments, body weight was not signiﬁcantly different between WRG and
CG. However at 6 months follow-up (during highest intensity of the
interventions), WRG had a signiﬁcantly larger reduction in body weight
than CG (-0.9 kg in WRG vs +0.9 kg in CG, p < 0.00), and a signiﬁcant
larger part of WRG (12%) fulﬁlled the pre-speciﬁed objective of 5 kg or
5% weight reduction than in CG (6%, p ¼ 0.04). After 2.5 years, subjects
compliant to the weight reduction intervention (6 visits and 7
lessons) showed a meanweight reduction of 1.4  5.5 kg, compared 0.1
 6.3 kg in the controls (p ¼ 0.22). Up to now, only 50% of the primary
outcome measure has been scored. Based on these data, in the present
population incidence of knee OA was 19%. To avoid publication of
unfounded study results, no interim analyses on the primary outcome
measure were performed. All primary outcomes will be available in
February 2012 and will be presented at the Congress.
Conclusions: The pragmatic tailor made intervention did not show
effects on body weight throughout the 2.5 years follow-up, but several
measures of weight reduction showed a signiﬁcant effect in favour of
WRG within the ﬁrst 6 months. Sample size calculations were based on
a 20% incidence in the control group, 10% incidence in the intervention
group and 20% lost to follow-up. So far, incidence number reached
expected levels and percentage lost to follow-up was considerably
lower than expected. Final results will be available at the OARSI World
Congress.
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CARTILAGE LOSS DURING SYMPTOMATIC MAINTENANCE AFTER
A CLINICALLY SIGNIFICANT WEIGHT LOSS IN OBESE
OSTEOARTHRITIS PATIENTS: A RANDOMIZED CONTROLLED TRIAL
M. Henriksen 1, R. Christensen 1,2, D.J. Hunter 3, E. Dam4,
S. Lohmander 2,5, M. Boesen 1,6, H. Gudbergsen 1, H. Bliddal 1. 1 The
Parker Inst., Copenhagen, Denmark; 2Univ. of Southern Denmark,
Odense, Denmark; 3Univ. of Sydney, Sydney, Australia; 4Biomediq,
Copenhagen, Denmark; 5Univ. of Lund, Lund, Sweden; 6Dept. of
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Purpose: Weight loss in overweight patients with knee osteoarthritis
(OA) is recommended because it effectively induces symptomatic relief.
However, maintaining weight loss and symptomatic relief is a chal-
lenge, and the effects of weight and symptom maintenance programs
on cartilage deterioration are unknown. The purpose of this study was
to compare cartilage loss in the knee joint over 1-year of dietary
consultancy or therapeutic exercise vs. control in obese knee OA
patients after a clinically signiﬁcant weight loss.
Methods: Obese individuals (>50 years) with knee OA (ACR criteria),
and motivated for weight loss, were enrolled in a 16-week weight loss
program that induced a clinically signiﬁcant weight loss (>10%). They
were then randomized to either 1-year maintenance program with [D]
continuous dietary consultations, or [E] knee exercise program super-
vised by a physical therapist or [C] a control group receiving no support
from the study team for 1 year. The primary endpoint was annual
change in total knee joint cartilage volume assessed by MRI. Secondary
outcomes included changes in the individual regional cartilage volumes
assessed by automatic segmentation of MRI and changes in average
knee symptoms measured as the mean of 4 out of the 5 KOOS subscales
(excluding sports and recreation subscale) over 1 year. The outcomes
were analyzed statistically using ANCOVAwith a factor for maintenance
group, adjusting for the level at baseline.
Results: 192 participants, mean age 63 years (SD 6), mean weight 103.2
kg (15.0), and BMI of 37.3 (4.8) were randomized (1:1:1; 64 patients in
each group). The average annual loss in total cartilage volume across
groups was 1,150 mm3. There were no statistically signiﬁcant group
differences in changes in cartilage volumes at the 1 year follow-up
(Table). The average symptoms deteriorated by 8.4 points (SE 1.1) across
groups. There were also no statistically signiﬁcant group differences for
the average symptoms (KOOS) or any of the other secondary outcomes.
Ancillary analysis showed that the annual changes in total cartilage
volume were not associated with annual changes in average symptoms
(r¼-0.007, P¼0.93).
Conclusion: This study showed no differences in knee joint cartilage
loss between obese knee OA patients who after a signiﬁcant weight loss
